Research Paper Volume 13, Issue 9 pp 12691—12709

Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis

Correlation between immune subgroups and the efficacy of immunotherapy. (A) Efficacy of immunotherapy in different immune subgroups. (B) Progression-free survival in different immune subgroups. (C) Expression differences of PD-1 (C1), PD-L1 (C2) and PD-L2 (C3) in different subgroups.

Figure 6. Correlation between immune subgroups and the efficacy of immunotherapy. (A) Efficacy of immunotherapy in different immune subgroups. (B) Progression-free survival in different immune subgroups. (C) Expression differences of PD-1 (C1), PD-L1 (C2) and PD-L2 (C3) in different subgroups.